incyte corp (INCY:NASDAQ GS)
Executive Profile*
Paul A. Friedman M.D.Chief Executive Officer, President, Director, Member of Non-Management Stock Option Committee and Member of Finance Committee, Incyte Corporation |
| Age | Total Calculated Compensation | This person is connected to 61 board members in 5 different organizations across 6 different industries. See Board Relationships |
| 69 | $3,019,660 As of Fiscal Year 2012 |
Background*
Dr. Paul A. Friedman, M.D. has been the Chief Executive Officer of Incyte Corporation since November 2001 and its President since May 2004. From 1998 to October 2001, Dr. Friedman served as the President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont Pharmaceuticals Company. From 1994 to 1998, he served as President of Research and Development of The DuPont Merck Pharmaceutical Company. From 1991 to 1994, he served as Senior Vice ...
Corporate Headquarters*Experimental StationWilmington, Delaware 19880 United States Phone: 302-498-6700 Fax: 302-425-2750 Board Members Memberships*2001-Present Chief Executive Officer, President, Director, Member of Non-Management Stock Option Committee and Member of Finance Committee 2004-N/A Former Director and Member of Nominating & Governance Committee 2008-Present Director and Member of Compensation Committee 2010-Present Director and Member of Compensation Committee 2013-Present Non-Executive Director 2013-Present Director
Education*BA 1964 Princeton University MD 1969 Harvard Medical School
Other Affiliations* |
Annual Compensation*
Stock Options*
Total Compensation*
|
| Recently Viewed | |||
| INCY:US | $23.04 USD | -0.13 |  |
COMPETITOR COMPENSATION
| Name | Position/ Company | Compensation |
| Harvey J. Berger M.D. | Principal Founder, Chairman of the Board, Chief Executive Officer, President and Chairman of Executive Committee Ariad Pharmaceuticals Inc. | $1.7M |
| Ron Squarer BSc (Biochemistry), MBA | Chief Executive Officer and Director Array BioPharma, Inc. | $193.6K |
| Michael M. Morrissey Ph.D. | Chief Executive Officer, President and Director Exelixis, Inc. | $1.1M |
| Werner Lanthaler MBA/MPA | Chief Executive Officer Evotec AG | €714.0K |
| Adelene Q. Perkins | Chairman of The Board, Chief Executive Officer and President Infinity Pharmaceuticals, Inc. | $536.0K | Compensation as of Fiscal Year 2012. |
Post a JobJobs
- Wilmington, DE | IncytePosted: May 15
- Wilmington, DE | IncytePosted: May 06
- Wilmington, DE | IncytePosted: May 06
- Wilmington, DE | IncytePosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact INCYTE CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
